Cargando…

Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma

The incidence of Human-papillomavirus-positive (HPV(+)) tonsillar and base-of-tongue squamous cell carcinoma (TSCC and BOTSCC, respectively) is increasing epidemically, but they have better prognosis than equivalent HPV-negative (HPV(−)) cancers, with roughly 80% vs. 50% 3-year disease-free survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Näsman, Anders, Holzhauser, Stefan, Kostopoulou, Ourania N., Zupancic, Mark, Ährlund-Richter, Andreas, Du, Juan, Dalianis, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156012/
https://www.ncbi.nlm.nih.gov/pubmed/34069114
http://dx.doi.org/10.3390/v13050910
_version_ 1783699338213457920
author Näsman, Anders
Holzhauser, Stefan
Kostopoulou, Ourania N.
Zupancic, Mark
Ährlund-Richter, Andreas
Du, Juan
Dalianis, Tina
author_facet Näsman, Anders
Holzhauser, Stefan
Kostopoulou, Ourania N.
Zupancic, Mark
Ährlund-Richter, Andreas
Du, Juan
Dalianis, Tina
author_sort Näsman, Anders
collection PubMed
description The incidence of Human-papillomavirus-positive (HPV(+)) tonsillar and base-of-tongue squamous cell carcinoma (TSCC and BOTSCC, respectively) is increasing epidemically, but they have better prognosis than equivalent HPV-negative (HPV(−)) cancers, with roughly 80% vs. 50% 3-year disease-free survival, respectively. The majority of HPV(+) TSCC and BOTSCC patients therefore most likely do not require the intensified chemoradiotherapy given today to head and neck cancer patients and would with de-escalated therapy avoid several severe side effects. Moreover, for those with poor prognosis, survival has not improved, so better-tailored alternatives are urgently needed. In line with refined personalized medicine, recent studies have focused on identifying predictive markers and driver cancer genes useful for better stratifying patient treatment as well as for targeted therapy. This review presents some of these endeavors and briefly describes some recent experimental progress and some clinical trials with targeted therapy.
format Online
Article
Text
id pubmed-8156012
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81560122021-05-28 Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma Näsman, Anders Holzhauser, Stefan Kostopoulou, Ourania N. Zupancic, Mark Ährlund-Richter, Andreas Du, Juan Dalianis, Tina Viruses Review The incidence of Human-papillomavirus-positive (HPV(+)) tonsillar and base-of-tongue squamous cell carcinoma (TSCC and BOTSCC, respectively) is increasing epidemically, but they have better prognosis than equivalent HPV-negative (HPV(−)) cancers, with roughly 80% vs. 50% 3-year disease-free survival, respectively. The majority of HPV(+) TSCC and BOTSCC patients therefore most likely do not require the intensified chemoradiotherapy given today to head and neck cancer patients and would with de-escalated therapy avoid several severe side effects. Moreover, for those with poor prognosis, survival has not improved, so better-tailored alternatives are urgently needed. In line with refined personalized medicine, recent studies have focused on identifying predictive markers and driver cancer genes useful for better stratifying patient treatment as well as for targeted therapy. This review presents some of these endeavors and briefly describes some recent experimental progress and some clinical trials with targeted therapy. MDPI 2021-05-14 /pmc/articles/PMC8156012/ /pubmed/34069114 http://dx.doi.org/10.3390/v13050910 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Näsman, Anders
Holzhauser, Stefan
Kostopoulou, Ourania N.
Zupancic, Mark
Ährlund-Richter, Andreas
Du, Juan
Dalianis, Tina
Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma
title Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma
title_full Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma
title_fullStr Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma
title_full_unstemmed Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma
title_short Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma
title_sort prognostic markers and driver genes and options for targeted therapy in human-papillomavirus-positive tonsillar and base-of-tongue squamous cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156012/
https://www.ncbi.nlm.nih.gov/pubmed/34069114
http://dx.doi.org/10.3390/v13050910
work_keys_str_mv AT nasmananders prognosticmarkersanddrivergenesandoptionsfortargetedtherapyinhumanpapillomaviruspositivetonsillarandbaseoftonguesquamouscellcarcinoma
AT holzhauserstefan prognosticmarkersanddrivergenesandoptionsfortargetedtherapyinhumanpapillomaviruspositivetonsillarandbaseoftonguesquamouscellcarcinoma
AT kostopoulououranian prognosticmarkersanddrivergenesandoptionsfortargetedtherapyinhumanpapillomaviruspositivetonsillarandbaseoftonguesquamouscellcarcinoma
AT zupancicmark prognosticmarkersanddrivergenesandoptionsfortargetedtherapyinhumanpapillomaviruspositivetonsillarandbaseoftonguesquamouscellcarcinoma
AT ahrlundrichterandreas prognosticmarkersanddrivergenesandoptionsfortargetedtherapyinhumanpapillomaviruspositivetonsillarandbaseoftonguesquamouscellcarcinoma
AT dujuan prognosticmarkersanddrivergenesandoptionsfortargetedtherapyinhumanpapillomaviruspositivetonsillarandbaseoftonguesquamouscellcarcinoma
AT dalianistina prognosticmarkersanddrivergenesandoptionsfortargetedtherapyinhumanpapillomaviruspositivetonsillarandbaseoftonguesquamouscellcarcinoma